40 related articles for article (PubMed ID: 11750838)
1. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM; Miller A; Smith J; Lichtman SM; Bookman M; Aghajanian C; Sabbatini P; Backes F; Cohn DE; Argenta P; Friedlander M; Goodheart MJ; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray H; Secord AA; Van Le L; O'Cearbhaill RE
Gynecol Oncol; 2023 Jul; 174():213-223. PubMed ID: 37229879
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 1989 Nov; 7(11):1748-56. PubMed ID: 2681557
[TBL] [Abstract][Full Text] [Related]
4. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function.
Molenaar-Kuijsten L; Pieters TT; Veldhuis WB; Moeskops P; Rijkhorst EJ; Dorlo TPC; Beijnen JH; Steeghs N; Rookmaaker MB; Huitema ADR
Br J Clin Pharmacol; 2023 Oct; 89(10):3016-3025. PubMed ID: 37194167
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.
Casal MA; Nolin TD; Beumer JH
Clin J Am Soc Nephrol; 2019 Apr; 14(4):587-595. PubMed ID: 30890575
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 2023 Oct; 41(28):4453-4454. PubMed ID: 37757592
[TBL] [Abstract][Full Text] [Related]
7. Improving Carboplatin Dosing Based on Estimated GFR.
Beumer JH; Inker LA; Levey AS
Am J Kidney Dis; 2018 Feb; 71(2):163-165. PubMed ID: 29217306
[No Abstract] [Full Text] [Related]
8. Carboplatin Dosing on the Basis of Renal Function: 30+ Years after Calvert.
Schwenk MH
Kidney360; 2024 Feb; 5(2):271-273. PubMed ID: 38233985
[No Abstract] [Full Text] [Related]
9. Guidelines for treatment of renal injury during cancer chemotherapy 2016.
Horie S; Oya M; Nangaku M; Yasuda Y; Komatsu Y; Yanagita M; Kitagawa Y; Kuwano H; Nishiyama H; Ishioka C; Takaishi H; Shimodaira H; Mogi A; Ando Y; Matsumoto K; Kadowaki D; Muto S
Clin Exp Nephrol; 2018 Feb; 22(1):210-244. PubMed ID: 28856465
[No Abstract] [Full Text] [Related]
10. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?
Delanaye P; Melsom T; Ebert N; Bäck SE; Mariat C; Cavalier E; Björk J; Christensson A; Nyman U; Porrini E; Remuzzi G; Ruggenenti P; Schaeffner E; Soveri I; Sterner G; Eriksen BO; Gaspari F
Clin Kidney J; 2016 Oct; 9(5):700-4. PubMed ID: 27679716
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two methods for carboplatin dosing in children with retinoblastoma.
Allen S; Wilson MW; Watkins A; Billups C; Qaddoumi I; Haik BH; Rodriguez-Galindo C
Pediatr Blood Cancer; 2010 Jul; 55(1):47-54. PubMed ID: 20486170
[TBL] [Abstract][Full Text] [Related]
12. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients.
Dooley MJ; Singh S; Rischin D
Br J Cancer; 2004 Mar; 90(5):991-5. PubMed ID: 14997195
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological factors influencing anticancer drug selection in the elderly.
John V; Mashru S; Lichtman S
Drugs Aging; 2003; 20(10):737-59. PubMed ID: 12875610
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
15. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
16. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
17. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
18. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
19. Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault.
Tsang C; Akbari A; Frechette D; Brown PA
J Oncol Pharm Pract; 2021 Mar; 27(2):368-375. PubMed ID: 33297846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
